News
Public · Published
From Near Miss To Crown Jewel: The Rise, Reign And Road Ahead For Merck's Keytruda
Merck's Keytruda remained the world's top-selling drug from 2023 through 2025, according to the article. First approved by the FDA in September 2014 for advanced melanoma, the immune-based cancer treatment has since gained approval for additional cancer types.
Published:
Updated:
What happened
Merck’s Keytruda remained the world’s top-selling drug from 2023 through 2025, according to the article. First approved by the FDA in September 2014 for advanced melanoma, the immune-based cancer treatment has since gained approval for additional cancer types.
Confirmed
Global impact / market context
Keytruda’s continued top-selling status and approvals across more cancer types indicate a broad commercial role for Merck’s drug. For investors, sales depend on its ability to keep serving patients and retain medical use as treatment options and regulatory approvals evolve.
Analyst inference
The article frames Keytruda as both a major seller and a treatment with reported patient impact, while noting its expansion beyond advanced melanoma. That combination links Merck’s revenue opportunity to continued clinical use and the scope of its approved cancer indications.
Analyst inference
What to watch
- Watch for further FDA label expansions, meaning approvals to use Keytruda for additional cancer types, since each could widen the group of patients eligible for treatment. Analyst inference
- The article proposes a forward-looking account of Keytruda’s road ahead, but supplies no specific sales forecast, new approval, or scheduled regulatory decision to assess. Confirmed
- Track whether Keytruda maintains its top-selling position beyond 2025; a decline could weaken the drug’s contribution to Merck’s revenue, while continued leadership would support it. Analyst inference
Evidence
- Original source link unavailable